Goldman Sachs analyst Madhu Kumar maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Neutral and raises the price target from $5 to $6.
Goldman Sachs Maintains Neutral on Fulcrum Therapeutics, Raises Price Target to $6
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.